Security Snapshot

MediWound Ltd. - Common Shares (MDWD) Institutional Ownership

CUSIP: M68830104

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2023

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Type / Class
Equity / Common Shares
Symbol
MDWD on Nasdaq
Shares outstanding
12,838,938
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • MDWD - MediWound Ltd. - Common Shares is tracked under CUSIP M68830104.
  • Latest finished 13F holder period is not available.
  • 2 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 1 to 0 between Q4 2022 and Q1 2023.
  • Reported value moved from $479,633 to $0.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC Evidence

Investment Quick Answers

What is CUSIP M68830104?
CUSIP M68830104 identifies MDWD - MediWound Ltd. - Common Shares in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Significant Owners of MediWound Ltd. - Common Shares (MDWD) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
HOLD Alapkezelo Zrt. 8.1% +23% 1,039,954 +48% HOLD Alapkezelo Zrt. 13 Feb 2026
Rosalind Advisors, Inc. 7% 0% 912,319 0% Rosalind Advisors, Inc. 31 Dec 2025

Institutional Holders of MediWound Ltd. - Common Shares (MDWD) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2023 Q1 0 $0 -$479,633 0
2022 Q4 36,502 $479,633 -$14,904,707 $13.14 1
2022 Q3 8,732,355 $12,156,900 +$7,886,736 $1.39 26
2022 Q2 3,060,032 $5,626,400 +$494,287 $1.84 19
2022 Q1 2,787,010 $5,545,527 -$1,735,379 $1.99 24
2021 Q4 3,655,370 $8,631,369 +$258,584 $2.36 27
2021 Q3 3,537,329 $11,810,598 -$1,010,498 $3.34 25
2021 Q2 3,555,747 $13,617,000 -$5,837,199 $3.83 23
2021 Q1 4,874,780 $26,170,480 +$652,531 $5.37 27
2020 Q4 4,815,044 $17,807,000 +$769,998 $3.70 26
2020 Q3 4,603,789 $17,306,000 +$273,265 $3.76 25
2020 Q2 4,541,601 $13,490,000 -$4,902,499 $2.97 23
2020 Q1 6,214,039 $9,756,000 -$982,416 $1.57 20
2019 Q4 6,818,630 $21,136,000 -$831,538 $3.10 23
2019 Q3 7,081,529 $22,565,000 -$2,317,194 $3.20 19
2019 Q2 7,812,066 $26,428,000 -$2,051,734 $3.38 24
2019 Q1 8,362,314 $41,812,000 +$1,415,133 $5.00 24
2018 Q4 8,111,968 $32,932,000 -$2,741,335 $4.06 21
2018 Q3 8,629,094 $53,199,185 -$1,620,579 $6.15 24
2018 Q2 8,809,937 $60,570,207 +$176,379 $6.90 19
2018 Q1 8,857,162 $46,061,156 -$153,501 $5.20 19
2017 Q4 8,889,781 $39,561,000 +$1,410,544 $4.45 22
2017 Q3 7,965,343 $42,498,000 +$14,965,316 $5.34 19
2017 Q2 5,152,069 $35,034,000 -$4,705,694 $6.80 19
2017 Q1 5,854,412 $38,639,000 -$638,538 $6.60 17
2016 Q4 6,004,784 $27,430,785 -$231,066 $4.58 20
2016 Q3 5,964,342 $45,921,090 -$21,022 $7.70 21
2016 Q2 5,785,106 $45,516,413 +$22,619,146 $7.89 18
2016 Q1 2,910,868 $23,489,719 +$44,635 $8.07 16
2015 Q4 2,903,686 $24,799,518 +$200,667 $8.54 18
2015 Q3 2,879,689 $21,970,890 +$2,483,340 $7.63 17
2015 Q2 2,555,675 $18,069,199 -$1,434,477 $7.07 17
2015 Q1 2,756,482 $20,149,213 +$803,653 $7.24 15
2014 Q4 2,650,826 $17,959,117 -$3,313,445 $6.66 16
2014 Q3 3,142,395 $19,716,000 -$4,131,129 $6.29 21
2014 Q2 3,581,061 $40,741,000 +$34,275,141 $11.38 21
2014 Q1 568,214 $8,188,000 +$8,188,000 $14.41 1
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .